A detailed history of Vanguard Group Inc transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 6,702,521 shares of MRSN stock, worth $12.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,702,521
Previous 6,274,370 6.82%
Holding current value
$12.5 Million
Previous $28.1 Million 52.07%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$2.0 - $4.45 $856,302 - $1.91 Million
428,151 Added 6.82%
6,702,521 $13.5 Million
Q1 2024

May 10, 2024

BUY
$2.16 - $5.94 $79,449 - $218,485
36,782 Added 0.59%
6,274,370 $28.1 Million
Q4 2023

Feb 14, 2024

BUY
$1.11 - $2.34 $57,126 - $120,428
51,465 Added 0.83%
6,237,588 $14.5 Million
Q3 2023

Nov 14, 2023

BUY
$1.06 - $3.91 $489,194 - $1.8 Million
461,504 Added 8.06%
6,186,123 $7.86 Million
Q2 2023

Aug 14, 2023

BUY
$3.08 - $9.55 $3.35 Million - $10.4 Million
1,086,127 Added 23.42%
5,724,619 $18.8 Million
Q1 2023

May 15, 2023

BUY
$4.0 - $7.02 $757,808 - $1.33 Million
189,452 Added 4.26%
4,638,492 $19.1 Million
Q4 2022

Feb 10, 2023

BUY
$5.65 - $7.86 $401,381 - $558,382
71,041 Added 1.62%
4,449,040 $26.1 Million
Q3 2022

Nov 14, 2022

SELL
$4.63 - $8.0 $1.65 Million - $2.85 Million
-355,732 Reduced 7.51%
4,377,999 $29.6 Million
Q2 2022

Aug 12, 2022

BUY
$2.84 - $5.0 $3.69 Million - $6.49 Million
1,298,461 Added 37.8%
4,733,731 $21.9 Million
Q1 2022

May 13, 2022

SELL
$3.74 - $6.63 $643,882 - $1.14 Million
-172,161 Reduced 4.77%
3,435,270 $13.7 Million
Q4 2021

Feb 14, 2022

SELL
$5.48 - $9.86 $406,413 - $731,247
-74,163 Reduced 2.01%
3,607,431 $22.4 Million
Q3 2021

Nov 12, 2021

BUY
$8.56 - $14.47 $4.28 Million - $7.24 Million
500,009 Added 15.72%
3,681,594 $34.7 Million
Q2 2021

Aug 13, 2021

BUY
$13.28 - $18.07 $42.3 Million - $57.5 Million
3,181,585 New
3,181,585 $43.2 Million

Others Institutions Holding MRSN

About Mersana Therapeutics, Inc.


  • Ticker MRSN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,169,296
  • Market Cap $182M
  • Description
  • Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...
More about MRSN
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.